BiotechTube

Oral prednisolone + Placebo for oral prednisolone

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Glycogen Storage Disease Type IA

Conditions

Glycogen Storage Disease Type IA

Trial Timeline

Nov 8, 2021 → Feb 5, 2026

NCT ID
NCT05139316

About Oral prednisolone + Placebo for oral prednisolone

Oral prednisolone + Placebo for oral prednisolone is a phase 3 stage product being developed by Ultragenyx Pharmaceutical for Glycogen Storage Disease Type IA. The current trial status is completed. This product is registered under clinical trial identifier NCT05139316. Target conditions include Glycogen Storage Disease Type IA.

What happened to similar drugs?

3 of 6 similar drugs in Glycogen Storage Disease Type IA were approved

Approved (3) Terminated (0) Active (3)
✅ALGLUCOSIDASE ALFA (MYOZYME)SanofiApproved
✅Avalglucosidase alfa (GZ402666)SanofiApproved
✅Avalglucosidase alfaSanofiApproved
🔄avalglucosidase alfaSanofiPhase 3
🔄Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)SanofiPhase 3
🔄Cipaglucosidase alfa + MiglustatAmicus TherapeuticsPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05139316Phase 3Completed

Competing Products

20 competing products in Glycogen Storage Disease Type IA

See all competitors
ProductCompanyStageHype Score
mRNA-3745ModernaPhase 2
0
alglucosidase alfaSanofiPre-clinical
26
avalglucosidase alfaSanofiPhase 3
44
MyozymeSanofiPhase 2/3
38
MyozymeSanofiPre-clinical
26
Avalglucosidase AlfaSanofiPhase 2
35
MyozymeSanofiPhase 2/3
38
ALGLUCOSIDASE ALFA (MYOZYME)SanofiApproved
43
Avalglucosidase alfa (GZ402666)SanofiApproved
47
Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)SanofiPhase 3
40
Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)SanofiPhase 2
39
Alglucosidase alfaSanofiPhase 2
35
Avalglucosidase alfaSanofiApproved
50
MyozymeSanofiPhase 1/2
32
Alglucosidase alfa GZ419829SanofiPre-clinical
30
alglucosidase alfa (recombinant human acid alpha-glucosidase [rhGAA])SanofiPre-clinical
26
alglucosidase alfaSanofiPre-clinical
26
Cipaglucosidase alfa + MiglustatAmicus TherapeuticsPhase 3
44
BEAM-301: Single dose of BEAM-301 administered by IVBeam TherapeuticsPhase 1/2
33
UX053 + Antipyretic + H2 Blocker + H1 BlockerUltragenyx PharmaceuticalPhase 1/2
18